GORMAN KEVIN CHARLES

Form 4

February 07, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

January 31, Expires:

OMB APPROVAL

2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Rep GORMAN KEVIN CH	_	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
		NEUROCRINE BIOSCIENCES INC [NBIX]	(Check all applicable)		
(Last) (First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	_X_ Director 10% OwnerX_ Officer (give title Other (specify		
12780 EL CAMINO REAL		02/05/2018	below) below) Chief Executive Officer		
(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person		
SAN DIEGO, CA 9213	0		Form filed by More than One Reporting Person		

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	TransactiorDisposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)				6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	02/05/2018		S <u>(1)</u>	3,125	D	\$ 83.0787 (2)	339,482	D	
Common Stock	02/05/2018		S(3)	2,858	D	\$ 83.465 (4)	342,874	D	
Common Stock	02/06/2018		M	100,000	A	\$ 5.76	442,874	D	
Common Stock	02/06/2018		S(5)	100,000	D	\$ 80.0662 (6)	342,874	D	
	02/06/2018		F(7)	4,091	D	\$ 82.48	347,033	D	

Edgar Filing: GORMAN KEVIN CHARLES - Form 4

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 ar
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option	\$ 5.76	02/06/2018		M	(A)	100,000	(8)	08/25/2021	Commo Stock
Stock Option	\$ 81.49	02/05/2018		A	104,200		<u>(9)</u>	02/05/2028	Commo Stock
Restricted Stock Unit	(10)	02/05/2018		A	18,400		<u>(11)</u>	<u>(11)</u>	Commo Stock
Restricted Stock Unit	<u>(10)</u>	02/05/2018		A	18,400		(12)	03/15/2021	Commo Stock

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
GORMAN KEVIN CHARLES 12780 EL CAMINO REAL SAN DIEGO, CA 92130	X		Chief Executive Officer				

Signatures

/s/ Darin Lippoldt, 02/07/2018 Attorney-in-Fact

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Reporting Owners 2

Edgar Filing: GORMAN KEVIN CHARLES - Form 4

Sale of 3,125 shares of common stock issued upon vesting of 6,250 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (3,125) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$81.20 to \$84.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
 - Sale of 2,858 shares of common stock issued upon vesting of 5,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,892) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$81.43 to \$84.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$80.00 to \$80.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Payment of tax liability by withholding 4,091 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (4,159) maintained by the Reporting Person.
- (8) Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on August 25, 2011 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- (9) Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
- (10) Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- (11) The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022.
- (12) A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.